Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A physiological human nutrition includes circadian feeding and nighttime fasting during sleep. There is increasing evidence, that this natural fasting episode over nighttime majorly contributes to repair processes of the human body. So far, intensive care patients are normally enterally fed continuously, so that there is no circadian nutrition and no nighttime fasting. An enteral nutrition for 12 hours followed by a fasting period of 12 hours supported by exogenous ketone salts potentially improves the reconstitution of ICU patients compared to ICU patients who are continuously enterally fed.
There is increasing evidence that a circadian rhythm of feeding (cyclic feeding) could be beneficial for critical ill patients. Cyclic feeding and fasting are assumed to have positive effects on the gut microbiome resulting in optimization of host responses to gastrointestinal pathogens. Another positive effect of cyclic feeding potentially results from activation of a "fasting response", inducing repair pathways such as ketogenesis, mitochondrial biogenesis, anti-inflammatory pathways, antioxidant defenses and autophagy processes. The activation of these repair pathways could diminish cellular stress and promote cellular recovery in critical ill patients. A randomized controlled trial by van Dyck et al. could show that fasting-mimicking intervals of 12 hours are sufficient to generate a metabolic fasting response without risking a caloric deficit. This fasting response can be enhanced by additional supplementation of exogenous ketones. A cyclic enteral nutrition with 12 hours of daytime feeding and 12 hours of ketogenic nighttime fasting compared to a continuous enteral feeding for 24 hours can potentially improve the reconstitution of critically ill Intensive Care patients. This improved reconstitution can be measured by maintenance of muscle mass (measured by ultrasound of the musculus rectus femoris), urea/creatinine ration, length of ventilation, length of ICU and hospital stay, 30-day mortality, ICU mobility scale.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Interventional: Cyclic enteral nutrition with ketogenic nighttime fasting | Active Comparator | Interventional group: 12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts. |
|
| Control: Conventional continuous enteral nutrition | No Intervention | Control group Continuous enteral nutrition for 24 hours (as per patients´ individual caloric requirements defined by indirect calorimetry). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate) | Other | 12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts. |
| Measure | Description | Time Frame |
|---|---|---|
| Loss of muscle mass | Loss of muscle mass via Ultrasound of M. rectus femoris of a predefined leg | From date of randomization until the date of ICU discharge up to 1 month |
| Progress of urea / creatinine ratio | Urea / creatinine ratio in the patients´ blood | From date of randomization until the date of ICU discharge up to 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Length of invasive and noninvasive ventilation | Length of invasive and noninvasive ventilation | From date of randomization until the date of ICU discharge up to 1 month |
| Length of ICU and hospital stay |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sandra E Stoll, MD, assProf. | Contact | +49221478 | 82054 | sandraemilystoll@googlemail.com |
| Fabian Dusse, PD, MD | Contact | +49221478 | 40806 | fabian.dusse@uk-koeln.de |
| Name | Affiliation | Role |
|---|---|---|
| Bernd W Böttiger, Prof | University Hospital Cologne | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anesthesiology and Intensive Care Medicine | Recruiting | Cologne | North Rhine-Westphalia | 50937 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009133 | Muscular Atrophy |
| ID | Term |
|---|---|
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
Not provided
Not provided
Monocentric, prospective, randomized, interventional trial
Not provided
Not provided
Not provided
Not provided
|
|
Length of ICU and hospital stay
| From date of randomization until the date of hospital discharge up to 6 months |
| 30 day mortality on day 30 | 30 day mortality on day 30 | From date of randomization 30 days |
| ICU mobility scale on discharge | ICU mobility scale (lowest score 0, highest score 10) | From date of randomization until the date of ICU discharge up to 1 month |
| D020763 |
| Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |